Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether he has had discussions with relevant stakeholders on the potential merits of emerging treatments from AstraZeneca for ovarian and kidney cancer being made available through the NHS.

Ministers and officials regularly discuss emerging treatments with a range of organisations.

The National Institute for Health and Care Excellence (NICE) is the independent body which makes evidence-based recommendations for the National Health Service on whether medicines represent a clinically and cost-effective use of resources. NICE assesses all new cancer medicines and is committed to publishing draft guidance at the time of licensing, with final guidance published within three months of licensing wherever possible.